Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Interest Expenses (2016 - 2017)

Heron Therapeutics filings provide 4 years of Interest Expenses readings, the most recent being $100000.0 for Q1 2017.

  • On a quarterly basis, Interest Expenses changed 0.0% to $100000.0 in Q1 2017 year-over-year; TTM through Dec 2017 was $100000.0, a 96.02% decrease, with the full-year FY2025 number at $9.6 million, up 59.23% from a year prior.
  • Interest Expenses hit $100000.0 in Q1 2017 for Heron Therapeutics, down from $1.3 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.3 million in Q4 2016 to a low of $71000.0 in Q1 2013.
  • Median Interest Expenses over the past 3 years was $207000.0 (2013), compared with a mean of $387250.0.
  • Biggest five-year swings in Interest Expenses: plummeted 64.85% in 2013 and later changed 0.0% in 2017.
  • Heron Therapeutics' Interest Expenses stood at $209000.0 in 2013, then surged by 507.66% to $1.3 million in 2016, then plummeted by 92.13% to $100000.0 in 2017.
  • The last three reported values for Interest Expenses were $100000.0 (Q1 2017), $1.3 million (Q4 2016), and $886000.0 (Q3 2016) per Business Quant data.